DAKS1, a Kunitz Scaffold Peptide from the Venom Gland of Deinagkistrodon acutus Prevents Carotid-Artery and Middle-Cerebral-Artery Thrombosis via Targeting Factor XIa

Zhiping Jia †, Yunyang Liu †, Xiaoru Ji, Yizheng Zheng ©, Zhengyang Li, Shuai Jiang ©, Hongjin Li and Yi Kong *©

School of Life Science and Technology, China Pharmaceutical University, 24 Tong Jia Street, Nanjing 210009, China; 3219030696@stu.cpu.edu.cn (Z.J.); 1821030696@stu.cpu.edu.cn (Y.L.); 1822030732@stu.cpu.edu.cn (X.J.); 3219030707@stu.cpu.edu.cn (Y.Y.); 3220030542@stu.cpu.edu.cn (Z.L.); 3219030711@stu.cpu.edu.cn (S.J.); 2020181453@stu.cpu.edu.cn (H.L.)
* Correspondence: yikong@cpu.edu.cn; Tel.: +86-025-832-712-82
† These authors contributed equally to this work.

Abstract: Scaffold-based peptides (SBPs) are fragments of large proteins that are characterized by potent bioactivity, high thermostability, and low immunogenicity. Some SBPs have been approved by the FDA for human use. In the present study, we developed SBPs from the venom gland of Deinagkistrodon acutus (D. acutus) by combining transcriptome sequencing and Pfam annotation. To that end, 10 Kunitz peptides were discovered from the venom gland of D. acutus, and most of which peptides exhibited Factor XIa (FXIa) inhibitory activity. One of those, DAKS1, exhibiting strongest inhibitory activity against FXIa, was further evaluated for its anticoagulant and antithrombotic activity. DAKS1 prolonged twofold APTT at a concentration of 15 µM in vitro. DAKS1 potently inhibited thrombosis in a ferric chloride-induced carotid-artery injury model in mice at a dose of 1.3 mg/kg. Furthermore, DAKS1 prevented stroke in a transient middle cerebral-artery occlusion (tMCAO) model in mice at a dose of 2.6 mg/kg. Additionally, DAKS1 did not show significant bleeding risk at a dose of 6.5 mg/kg. Together, our results indicated that DAKS1 is a promising candidate for drug development for the treatment of thrombosis and stroke disorders.

Keywords: Kunitz; scaffold-based peptides; Deinagkistrodon acutus; DAKS1; Factor XIa; thrombosis

1. Introduction

Scaffold-based peptides are fragments of large proteins that play an important role in biological processes, and are characterized by high thermostability and low immunogenicity [1–3]. Their structures are similar to those of antibodies; each scaffold includes a constant region, which provides a stable secondary structure, and one or more variable loops, which are a response for binding to given targets. Some of these SBPs were approved by the FDA for human use [4,5], and many are currently being evaluated preclinically or in clinical trials, such as Kunitz domains, adnectins, anticalins, avimers, Fynomers, knottins, affibodies, β-hairpin mimetics, and DARPs [2,6].

Kunitz domains are derived from the active motif of Kunitz-type protease inhibitors, and they mainly inhibit the function of protein-degrading enzymes or, more specifically, they are serine protease inhibitors [7–9]. Kunitz SBPs are relatively small with a length of about 50 to 60 amino acids and a molecular weight of 6–7 kDa [10]. Ecallantide, a Kunitz scaffold-based inhibitor of kallikrein, was approved by the FDA in 2012 for the treatment of hereditary angioedema [11–13]. Depelstat, a Kunitz scaffold-based peptide, is a potent and selective inhibitor of human neutrophil elastase that mediates inflammation and contributes to lung damage in cystic fibrosis [14,15]. Depelstat can reduce neutrophil transepithelial migration and inflammation ex vivo [16]. Therefore, Kunitz SBPs are promising compounds for the treatment of serine protease-related diseases.
FXIa is an important serine protease, and plays a significant role in the intrinsic pathway [17]. Recent clinical studies showed that patients with FXI deficiency had reduced incidence of deep-vein thrombosis and ischemic stroke [18,19]. FXI−/− mice were protected from FeCl3-induced carotid-artery thrombus formation [20–22]. This evidence supports that FXI is a good target for antithrombotic drug discovery. Many Kunitz scaffold peptide inhibitors targeting FXI were discovered in recent years, such as PN2KPI from the human platelet [23,24], Faxsxiator from Bungarus fasciatus [25], and Ir-CPI from Ixodes ricinus [26,27].

In the current study, we developed Kunitz SBPs from the venom gland of D. acutus by combining transcriptome sequencing and Pfam annotation. To that end, 10 Kunitz SBPs were discovered from the venom gland of D. acutus. These peptides were cloned and expressed, and their inhibitory activity against FXIa was tested. DAKS1, which exhibited the strongest inhibitory activity towards FXIa, was further assessed for its anticoagulant activity in vivo.

2. Results
2.1. Ten Kunitz SBPs Discovered from Venom Gland of D. acutus

The transcriptome of the venom gland of D. acutus was analyzed using Illumina Hiseq 4000 sequencing, and 45,321 unigenes with length distribution N50 = 1462 were discovered. Unigenes were annotated by using the GO, COG, KEGG, Nr, Nt, Swissprot, and Interpro databases, separately, and 11 full-length Kunitz proteins (Table S1) were selected from the annotated transcriptome library on the basis of a “Kunitz” keyword search. The 12 Kunitz SBPs sequences in these proteins were recognized by the Pfam database. When the E-value was below 10−15, 2 Kunitz peptides sequences were screened out, and 10 classical Kunitz peptides remained (Figure S1a,b); those Kunitz peptides were named DAKS1-10 (Table 1 and Figure 1c). The conserved amino acids in the DAKS1-10 peptides are shown in Figure 1d. Classical Kunitz domains consist of 50–60 amino acids and adopt a conserved structural fold with two antiparallel β-sheets and one or two alpha helical regions that are stabilized with three highly conserved disulfide bridges with the bonding pattern of C1–C6, C2–C4, and C3–C5 [7,28,29] (Figure 1a,b).

| Peptide Name | Unigene_id | Sequences |
|--------------|------------|-----------|
| DAKS1        | Unigene7405_D_acutus | AVCSQEA\MTGPCR\AVMPR\WYFDYM\KKCIRF\FYGC\GNGN\N\FSEEC\YMCAV\CKKM |
| DAKS2        | Unigene2097_D_acutus_1 | DRCHSSKM\VGP\CAR\FHR\WYFI \LRTCKMV\FYG\CKGNK\NLYFEECH\WC\NQC\TGD |
| DAKS3        | Unigene2097_D_acutus_2 | EFCAQMV\PCR\AR\FHR\WYD\LRTCKMV\FYG\CKGNK\NLYFEECH\WC\NQC\TGD |
| DAKS4        | Unigene24735_D_acutus_2 | DLQCLQPE\EGC\PD\LPRW\FW\NPK\DK\FDFG\CAG\N\NFK\RR\CRL\CRCR |
| DAKS5        | Unigene5437_D_acutus     | DICQK\RDC\G\C\N\L\F\D\T\F\C\W\C\G\N\E\N\F\T\Q\D\E\C\K\V\S\A\H |
| DAKS6        | Unigene2946_D_acutus_1  | SYCVP\MDP\TG\CE\GL\PR\W\NY\PL\TE\KG\R\TY\GG\C\E\NG\KN\N\N\F\F\E\E\C\M\E\C\R\G\T |
| DAKS7        | Unigene2946_D_acutus_2  | DHCLAP\Y\KG\CE\GL\PR\W\NY\PL\TE\KG\R\TY\GG\C\E\NG\KN\N\N\F\F\E\E\C\M\E\C\R\G\T |
| DAKS8        | Unigene20491_D_acutus_1 | AFCLL\N\D\PV\CV\RG\L\PY\FY\NK\ES\Q\C\EK\F\YG\C\G\N\E\N\F\S\L\I\E\C\Q\N\T\C\D\R\V |
| DAKS9        | Unigene20491_D_acutus_3 | SICALK\AD\G\PC\K\A\HT\RY\HD\I\H\HR\C\E\F\SN\F\G\C\G\N\E\N\F\S\L\I\E\C\Q\N\T\C\D\R\V |
| DAKS10       | Unigene20491_D_acutus_3 | SLC\VMP\MD\RG\LC\ANE\KR\FF\YN\QT\G\CR\PS\YS\TG\C\G\N\E\N\F\S\R\KAC\V\Q |

2.2. FXIa Inhibitory Activity of 10 Kunitz Peptides Tested by Substrate Chromogenic Method

To test whether DAKS1-10 has inhibitory activity towards FXIa, genes of DAKS1-10 were cloned into the pPIC9k, and were expressed using Pichia pastoris GS115. After purification by using ammonium sulfate precipitation and affinity chromatography on a UniNTA-80Ni column, the inhibitory activity of DAKS1-10 towards FXIa was tested with the substrate chromogenic method. Results showed that most of the Kunitz domains can inhibit FXIa; one of those, DAKS1, had the strongest inhibitory activity (Table 2). The yield of DAKS1 was 10 mg peptides per liter of fermentation broth. It showed one band in Tricine–SDS-PAGE analysis (Figure 2a), and showed a purity of 90% in HPLC analysis (Figure 2b). LC–Q-TOF–MS indicated that the MW of DAKS1 was 7434.3658 ± 0.0174 Da (Figure 2c), which is identical to the theoretical MW of 7434.35 Da.
Figure 1. Structure and sequence characteristics of Kunitz peptides DAKS1-10. (a) Schematic representation of disulfide bonding pattern of Kunitz domains. Conserved cysteine residues are marked with red. “x” represents random amino acid residues. (b) Crystal structure of PN2KPI (PDB: 1ZJD). Antiparallel β-sheets are marked in yellow, alpha helical is marked in red, and β-turn is marked in blue. (c) Alignment of DAKS1-10 and PN2KPI. “*” indicates fully conserved amino acid residue, “:” indicates amino acid residue with similar properties, and “.” indicates amino acid residue with weak similar properties. (d) Sequence logo of amino acid sequences of DAKS1-10. Logo represents each column of the alignment in a stack of letters, with the height of each letter proportional to the observed frequency of the corresponding amino acid residue, and the overall height of each stack proportional to the sequence conservation.

Table 2. Inhibitory activity of DAKS1-10 against FXIa.

| Peptide Name | Concentration (uM) | Inhibition Rate (%) |
|--------------|--------------------|---------------------|
| DAKS1        | 7.5                | 98.13 ± 0.31        |
|              | 0.15               | 91.20 ± 0.31        |
|              | 0.05               | 63.51 ± 0.96        |
| DAKS2        | 7.5                | 98.34 ± 0.25        |
|              | 0.15               | 91.20 ± 0.31        |
|              | 0.05               | 63.51 ± 0.96        |
| DAKS3        | 7.5                | 98.34 ± 0.25        |
|              | 0.15               | 91.20 ± 0.31        |
|              | 0.05               | 63.51 ± 0.96        |
| DAKS4        | 7.5                | 98.34 ± 0.25        |
|              | 0.15               | 91.20 ± 0.31        |
|              | 0.05               | 63.51 ± 0.96        |
Table 2. Cont.

| Peptide Name | Concentration (uM) | Inhibition Rate (%) |
|--------------|--------------------|---------------------|
| DAKS5        | 7.5                | −14.24 ± 1.08       |
| DAKS6        | 7.5                | −8.840 ± 0.75       |
| DAKS7        | 7.5                | 6.237 ± 1.92        |
| DAKS8        | 7.5                | −8.820 ± 2.12       |
| DAKS9        | 7.5, 0.15, 0.05    | 69.07 ± 2.08, 27.16 ± 0.98, 16.17 ± 1.28 |
| DAKS10       | 7.5                | −10.03 ± 1.24       |

Inhibition of DAKS1-10 against FXIa assessed in chromogenic substrate assay. Results obtained from 3 independent experiments.

Figure 2. Characterization of DAKS1. (a) Tricine–SDS-PAGE analysis of DAKS1. (b) HPLC analysis of DAKS1. (c) LC–Q-TOF–MS analysis of DAKS1.
2.3. DAKS1 Is a Potent FXIa Inhibitor

DAKS1 inhibited the amidolytic activity of FXIa towards its substrate S-21 (66) in a dose-dependent manner with an IC\(_{50}\) value of 21.92 ± 0.73 nM (Figure 3a,b). We tested the inhibitory activity of DAKS1 to other serine proteases, such as thrombin, FXIIa, FXa, kallikrein, and trypsin, and results showed that DAKS1 did not exhibit inhibitory activity to thrombin and FXIIa. DAKS1 had little inhibitory function towards FXa and kallikrein when a 1:125 molar ratio of FXa and DAKS1 resulted in efficient FXa inhibition of 70%, whereas a molar ratio of 1:6000 of FXa and DAKS1, and 1:3000 of kallikrein and DAKS1 resulted in FXa and kallikrein inhibition of 27.45% and 62.28%, respectively (Table 3). However, DAKS1 had strong inhibitory function to trypsin with an IC\(_{50}\) value of 34.26 nM (Figure S2a,b). Classical Kunitz peptide PN2KPI secreted from the human platelet [23,24] was cloned and expressed in our laboratory, and its inhibitory activity towards various serine proteases was also determined. PN2KPI had potent inhibitory activity towards FXI and trypsin with IC\(_{50}\) values of 8.01 ± 3.92 nM (Figure 3c,d) and 25.01 ± 4.94 nM (Figure S2c,d), respectively, and showed no or weak inhibitory activity towards other serine proteases (Table 3).

**Figure 3.** DAKS1 is a potent inhibitor of FXIa. (a) Inhibitory activity of DAKS1 towards FXIa. Reactions began by the addition of CS-21 (66) (250 µM) to a mixture containing DAKS1 (0–250 nM) incubated for 60 min with FXIa (0.5 nM). Substrate hydrolyzed and monitored at 405 nm for 60 min. (b) Determination of IC\(_{50}\) of DAKS1. Plot of inhibition rate (%) vs. log DAKS1 concentrations fitted by nonlinear regression, and value of IC\(_{50}\) was obtained by fit log(inhibitor) vs. normalized response-variable slope. (c) Inhibitory activity of PN2KPI towards FXIa. Reactions began by the addition of CS-21 (66) (250 µM) to a mixture containing PN2KPI (0–50 nM) incubated for 60 min with FXIa (0.5 nM). Substrate was hydrolyzed and monitored at 405 nm for 60 min. (d) Determination of IC\(_{50}\) of PN2KPI. Plot of inhibition rate (%) vs. log PN2KPI concentrations fitted by nonlinear regression, and value of IC\(_{50}\) was obtained by fit log(inhibitor) vs. normalized response-variable slope. Data presented as mean ± standard deviation (SD) of three independent experiments.
Table 3. Protease specificity of DAKS1 and PN2KPI.

| Inhibitor | Molar Ratio | Inhibition, % |
|-----------|-------------|---------------|
| DAKS1     | 1:125, FXIa:inhibitor | >70           |
| PN2KPI    | 1:13.3, FXIa:inhibitor | >90           |
| DAKS1     | 1:6000, FXa:inhibitor | 27.45         |
| PN2KPI    | 1:504, FXa:inhibitor | 55.84         |
| DAKS1     | 1:6000, thrombin:inhibitor | 1.54         |
| PN2KPI    | 1:2066, thrombin:inhibitor | −39.51       |
| DAKS1     | 1:3000, kallikrein:inhibitor | 62.28        |
| PN2KPI    | 1:206, kallikrein:inhibitor | 16.65        |
| DAKS1     | 1:500, trypsin:inhibitor | 68.46         |
| PN2KPI    | 1:52, trypsin:inhibitor | 87.41         |
| DAKS1     | 1:6000, FXIIa:inhibitor | 0             |
| PN2KPI    | 1:1033, FXIIa:inhibitor | 19.58         |

Inhibition of DAKS1 against FXIa, FXa, thrombin, kallikrein, trypsin, and FXIIa assessed in chromogenic substrate assay. Inhibitor was incubated with the respective protease at the indicated molar ratio in the presence of a specific protease substrate. Results obtained from 3 independent experiments. PN2KPI served as control inhibitor.

2.4. DAKS1 Prolonged APTT in Mouse Plasma

FXIa belongs to intrinsic coagulation factors, and its inhibition leads to the prolongation of APTT, and not PT [30,31]. DAKS1 significantly prolonged APTT in a dose-dependent manner at a concentration ranging from 1.5 µM to 15 µM. As shown in Figure 4a,b, APTT and PT in the saline-treated group were 43.13 ± 3.13 s and 10.15 ± 0.35 s (mean ± SD, n = 3), respectively. In the DAKS1-treated groups, APTT significantly increased to 85.63 ± 2.32, 73.87 ± 6.25, and 67.60 ± 2.26 s at doses of 15, 10, and 7.5 µM (p < 0.0001 versus saline), respectively. For PT, at a high tested dose of 15 µM, DAKS1 did not significantly prolong its time when compared to the saline group (p > 0.05). PN2KPI significantly prolonged APTT in a dose-dependent manner at a concentration ranging from 2 to 19 µM. At doses of 5, 9, and 19 µM, the APTT were 52.10 ± 8.06, 55.90 ± 5.32, and 59.40 ± 2.62 s (p < 0.0001 versus saline), respectively (Figure 4c,d).

2.5. DAKS1 Inhibited Ferric Chloride-Induced Carotid-Artery Thrombosis in Mice

The effect of DAKS1 on thrombosis was evaluated by a ferric chloride-induced carotid-artery injury model in C57BL/6J male mice. Heparin sodium, which is clinical antithrombotic medicine, was used as a positive control. As shown in Figure 5a,b, times to occlusion were not significantly different between vehicle group (4.29 ± 0.43 min, mean ± SD, n = 5) and 0.26 mg/kg DAKS1-treated group (5.36 ± 1.37 min, mean ± SD, n = 5). DAKS1, at a dose of 1.3 mg/kg, significantly prolonged times to occlusion (20.95 ± 12.40 min, mean ± SD, n = 5). Occlusion did not happen within 30 min in three mice. While occlusion appeared at about 6 minutes in the two other mice, and more than 1 minute later, the thrombosis was flushed away. At a dose of 2.6 mg/kg, no DAKS1-treated mice formed occlusive thrombi within 30 min (30.00 ± 0.00 min, mean ± SD, n = 5), which was similar to that of heparin sodium. At a dose of 2.6 mg/kg of PN2KPI, occlusion did not happen within 30 min in two mice, and the occlusion appeared in three mice. At a high dose of 5.2 mg/kg, PN2KPI produced a similar effect as that of DAKS1 at 2.6 mg/kg (Figures 5c and S3a,b). The vessel sections of injured carotid artery stained by hematoxylin and eosin (H&E) showed that the thrombi in the lumen of the vessel of DAKS1-treated mice were smaller than those that appeared in vehicle group (Figure 5d).
Figure 4. DAKS1 prolonged plasma coagulation time. Effects on APTT and PT of DAKS1 and PN2KPI evaluated using platelet-poor plasma (PPP). (a) DAKS1 significantly prolonged APTT in a dose-dependent manner at a concentration ranging from 1.5 to 15 μM. (b) DAKS1 could prolong APTT by about 2 times, but not prolong PT at the same concentration. (c) PN2KPI significantly prolonged APTT in a dose-dependent manner at a concentration ranging from 2 to 19 μM. (d) PN2KPI could prolong APTT by about 1.5 times, but not prolong PT at 20 μM. Data presented as mean ± SD of three independent experiments. **** \( p < 0.0001 \) versus vehicle, * \( p < 0.05 \) versus vehicle by one-way ANOVA and Dunnett’s multiple-comparisons test, and vehicle means a lack of addition of DAKS1 or PN2KPI.

2.5. DAKS1 Inhibited Ferric Chloride-Induced Carotid-Artery Thrombosis in Mice

The effect of DAKS1 on thrombosis was evaluated by a ferric chloride-induced carotid-artery injury model in C57BL/6J male mice. Heparin sodium, which is clinical antithrombotic medicine, was used as a positive control. As shown in Figure 5a,b, times to occlusion were not significantly different between vehicle group (4.29 ± 0.43 min, mean ± SD, \( n = 5 \)) and 0.26 mg/kg DAKS1-treated group (5.36 ± 1.37 min, mean ± SD, \( n = 5 \)). DAKS1, at a dose of 1.3 mg/kg, significantly prolonged times to occlusion (20.95 ± 12.40 min, mean ± SD, \( n = 5 \)). Occlusion did not happen within 30 min in three mice. While occlusion appeared at about 6 minutes in the two other mice, and more than 1 minute later, the thrombosis was flushed away. At a dose of 2.6 mg/kg, no DAKS1-treated mice formed occlusive thrombi within 30 min (30.00 ± 0.00 min, mean ± SD, \( n = 5 \)), which was similar to that of heparin sodium. At a dose of 2.6 mg/kg of PN2KPI, occlusion did not happen within 30 min in two mice, and the occlusion appeared in three mice. At a high dose of 5.2 mg/kg, PN2KPI produced a similar effect as that of DAKS1 at 2.6 mg/kg (Figure 5c and Figure S3a,b). The vessel sections of injured carotid artery stained by hematoxylin and eosin (H&E) showed that the thrombi in the lumen of the vessel of DAKS1-treated mice were smaller than those that appeared in vehicle group (Figure 5d).

2.6. DAKS1 Inhibited Stroke in Mice

A tMCAO model in mice was used to evaluate the protective potency of DAKS1. As shown in Figure 6a,b, DAKS1 at 2.6 mg/kg significantly reduced the cerebral infarct area compared with those from a control group. The cerebral infarct area decreased from ~39.07% to ~16.45% (Figure 6c). Zea Longa and Bederson scores were used to assess neurological function, and results showed that DAKS1 could reduce ischemic stroke (Figure 6d,e).

2.7. DAKS1 Did Not Show Bleeding Risk in Mice

The bleeding risk of DAKS1 was measured by mouse-tail cutting assay. Doses of DAKS1 were designed as 3.25 and 6.5 mg/kg, which represent 2.5 and 5 times the efficient dose (1.3 mg/kg) used for ferric chloride-induced carotid-artery thrombosis study, and heparin sodium (2.7 mg/kg) was used as a positive control. As shown in Figure 5e, DAKS1 did not significantly prolong bleeding time, even at a high dose of 6.5 mg/kg (12.93 ± 5.14 min, mean ± SD, \( n = 6 \)), compared with the vehicle group (6.26 ± 2.90 min, mean ± SD, \( n = 6 \)), but heparin-treated mice were unable to stop tail bleeding within 20 min (>20.00 ± 0.00 min, mean ± SD, \( n = 6 \)).
Figure 5. DAKS1 inhibited thrombosis in a FeCl₃-induced carotid-artery injury model. Ten min after FeCl₃-induced injury, DAKS1 (0.26, 1.3, and 2.6 mg/kg) and heparin sodium (2.7 mg/kg) were injected by tail vein. (a) After treatment with 6% FeCl₃, blood flow at region of interest (ROI) was monitored at 0, 5, 10, 15, 20, 25, and 30 min. (b) Effects of DAKS1 (0.26, 1.3, and 2.6 mg/kg), and heparin sodium (2.7 mg/kg) on the inhibition of thrombosis. (c) Effects of PN2KPI (1.3, 2.6, and 5.2 mg/kg) on inhibition of thrombosis. (d) H&E staining micrographs of carotid-artery samples from a control mouse and the mouse administered with DAKS1 (0.26 and 2.6 mg/kg). (e) Bleeding time of DAKS1 in mice. Fifteen minutes after the administration of DAKS1 (3.25, 6.5 mg/kg), heparin sodium (2.7 mg/kg) and the NS, a 2 mm long tail tip was cut from the mice, and the remaining tail was immersed immediately into saline at 37 °C. Accumulated bleeding time (including periods of rebleeding) was recorded over a 20 min period. NS: normal saline. Data presented as mean ± SD (n = 6). ** p < 0.05, *** p < 0.001, **** p < 0.0001 versus NS, analyzed by one-way ANOVA, followed by Dunnett’s multiple comparison test.
DAKS1 was designed as 3.25 and 6.5 mg/kg, which represent 2.5 and 5 times the efficient antithrombotic dosage in a mouse-tail cutting assay, indicating that DAKS1 is a promising candidate for drug development for the treatment of thrombosis and stroke disorders.

3. Discussion

We discovered 10 Kunitz scaffold peptides from the venom gland of *D. acutus*, and most of those peptides exhibited FXIa inhibitory activity, determined by the chromogenic substrate method. DAKS1, exhibiting strongest inhibitory activity against FXIa, was further evaluated for its anticoagulant activity. Results showed that DAKS1 prolonged APTT, potently inhibited thrombosis formation in a ferric chloride-induced carotid thrombus formation model, and strongly prevented stroke in a tMCAO model. Interestingly, this Kunitz peptide did not significantly prolong bleeding time, even at five times the effective antithrombotic dosage in a mouse-tail cutting assay, indicating that DAKS1 is a promising candidate for drug development for the treatment of thrombosis and stroke disorders.

Protein scaffolds are a wide research focus because they can be used as antibody replacement therapy [32–35]. Scaffold-based specific peptides are usually developed by using display technologies, such as phage, yeast, or ribosome/mRNA displays [36]. With these technologies, a peptide library is built by the artificial random assembly of amino acids, but scaffolds used in drug studies are originally born from natural proteins that play an important role in biological processes [37–39]. Biological evolution should be a more rational method for producing bioactivity protein scaffolds. Snake venoms are a weapon library formed through millions of years of adaptive evolution for their prey and defense in the natural environment [40,41]. *D. acutus* is a poisonous snake, and its venom, and 10 Kunitz peptides were found. Those Kunitz peptides were then cloned and expressed in *P. pastoris*, and inhibitory activity

![Image](https://via.placeholder.com/150)

**Figure 6.** DAKS1 protected from ischemic stroke in mice. Cerebral ischemia and neurological damage evaluated in a tMCAO model. (a) Representative coronal brain sections 24 h after tMCAO from mice treated with saline. Pale area represents ischemic infarctions. Mice treated with DAKS1 (b). (c) Brain infarct area measured by image J (n = 6). (d,e) Bederson and Zea Longa scores in respective groups after 24 h of tMCAO. Data represent mean ± SD (n = 6), ***p < 0.001, ****p < 0.0001 by unpaired t-Test.
towards FXIa, a serine protease, was tested. Results showed that most of them could inhibit FXIa. DAKS1, which exhibited the strongest inhibitory activity against FXIa. The systemic bioactivity study of DAKS1 was further performed, including other coagulant factors inhibition in vitro, and antithrombosis and preventing stroke in vivo.

DAKS1 displayed potent inhibition activity to FXIa with an IC$_{50}$ value of 21.92 ± 0.37 nM, had strong inhibitory action to trypsin, and had no or weak inhibitory activity on FXa, FXIIa and thrombin. Fasxiator [25] is a 7 kDa Kunitz scaffold-based peptide from the venom of the Bungarus fasciatus snake with weaker inhibitory activity (IC$_{50}$ = 1.5 µM) than that of DAKS1, while Desmolaris [30], a Kunitz domain protein from the salivary gland of a vampire bat, has poor selectivity towards coagulation factors (K$_i$ for FXIa = 12.35 nmol L$^{-1}$, K$_i$ for FXa = 15.06 nmol L$^{-1}$). Ir-CPI, a Kunitz peptide from Ixodes ricinus, binds both to FXIa, and to FXIIa and plasma kallikrein [26]. PN2KPI [23,47], a Kunitz peptide secreted from platelet [24], is a potent inhibitor of FXIa. DAKS1 showed 68% identity with PN2KPI, aligned by using BLAST. PN2KPI was cloned, expressed, and purified as a control in the present study (Figure 1c), and its IC$_{50}$ value to FXIa was 8.01 ± 3.92 nM, as tested in our laboratory. The anticoagulant activity of DAKS1 and PN2KPI was further evaluated by using APTT and PT assays. Compared with the negative control, DAKS1 prolonged twofold APTT at a concentration of 15 µM. However, PN2KPI only prolonged 1.5-fold APTT, even if its concentration was increased to 19 µM, indicating that, though the inhibitory activity of DAKS1 towards FXIa was weaker than that of PN2KPI in the amidolytic activity test of the enzyme, the ability of DAKS1 for prolonging APTT was stronger than that of PN2KPI.

Ferric chloride-induced carotid thrombus formation model in mice was used to evaluate the antithrombotic properties of DAKS1 and PN2KPI. Results showed that DAKS1 could inhibit thrombus formation in a dose-dependent manner. At a concentration of 2.6 mg/kg, DAKS1 thoroughly inhibited thrombus formation in carotid-artery vessels, which was similar to heparin sodium, antithrombotic medicine widely used in clinics. PN2KPI, at a dose of 2.6 mg/kg, partially inhibited thrombi formation; at a higher dose of 5.2 mg/kg, it could totally inhibit thrombus formation, indicating that DAKS1 exerted stronger antithrombotic activity than that of PN2KPI in vivo, which is consistent with results in the APTT assay. The effect of DAKS1 on thrombosis was further investigated by using a transient cerebral-ischemia model in mice. DAKS1 reduced the cerebral infarct area. The Bederson score is a standard method to measure neurological deficits following stroke according to resistance to lateral push, forelimb flexion, and circling behavior [48]. The Zea Longa scoring method is similar to the Bederson method. Scores were measured as follows: 0, no symptom of neurological impairment; 1, the contralateral forelimb is unable to contract when the tail is lifted; 2, inward rotation when walking; 3, tilted inwards when walking; 4, fails to spontaneously walk and loss of consciousness [49]. Neurologically impaired animals have a higher score than that of non-neurologically impaired animals. Results of Bederson and Zea-longa scores indicated that DAKS1 protected from neurological impairment. A number of antithrombotic drugs are associated with bleeding complications [50,51]. DAKS1 did not show significant bleeding risk at 5 times the dose of the efficient dose used for in vivo antithrombotic studies. These results indicated that DAKS1 may be an excellent candidate for the development of clinical antithrombotic and anti-ischemic stroke drugs.

4. Materials and Methods

4.1. Materials and Reagents

Factor Xa, thrombin, Factor XIIa, Pefachrome FXIIa/TH 5253 (H-D-CHA-Gly-Arg-pNA·2AcOH), CS-11 (22) (Bz-Ile-Glu (yOCH3)-Gly-Arg-pNa and Bz-Ile-Glu (yOH)Gly-Arg-pNa), CS-31 (02) (D-Pro-Phe-Arg-pNa, 2HCl), CS-21 (66) (p-Glu-Pro-Arg-pNa·HCl) and CS-01 (38) (H-D-Phe-Pip-Arg-pNa, 2HCl) were from Hyphen-Biomed (Neuville Sur Oise, France); HFXIa was from Enzyme Research Laboratories, (South Bend, IN, USA); kallikrein was from AssayPro LLC, (St. Charles, MO, USA). APTT and PT reagents were from Taizhou Zhongqinshidi Biotechnology Co., Ltd., (Beijing, China); FeCl$_3$ was from
Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China); TTC was from Sigma (T8877-5G, St. Louis, MO, USA). All other chemicals used in this study were of analytical grade.

4.2. Animals Samples

C57BL/6J male mice were obtained from the Comparative Medicine Centre of Yangzhou University (Yangzhou, Jiangsu province, China). All animals were housed under controlled temperature (21–25 °C) and light (12 h light, 12 h dark), with ad libitum access to food and water for one week before experiments. All experiments were performed according to the guidelines and the regulations of the Ethical Committee of China Pharmaceutical University (CPU2019-S020, 19 December 2019).

4.3. Preparation of Venom Gland of D. acutus

The adult D. acutus was captured in the Yujiang Caihong snake farms (Yujiang county, Yingtan city, Jiangxi province, China). The snake was allowed to rest for three days to maximize transcription. Venom glands were promptly removed, washed in DNase/RNase-Free, and then placed into a tube with 10 mL TRI Reagent (Sigma, St. Louis, MO, USA). The tube was sent to the Beijing Genomic Institute, BGI (Shenzhen, China) for transcriptome sequencing.

4.4. Preparation of RNA Library and Sequencing

The library for the whole RNA sequencing was prepared through a standard protocol established by the Beijing Genomic Institute, BGI (Shenzhen, China): enrich mRNA with magnetic beads with Oligo (dT), synthesize the first-strand cDNA using the interrupted mRNA as a template, and then synthesize the second-strand cDNA. 3’ DNA adaptor was ligated to the digested DNA fragments, and products were amplified using PCR. Lastly, RNA deep sequencing was performed on the Illumina Hiseq automatic sequencing platform.

4.5. Bioinformatic Processing

The RNA sequencing, assembly, and assessment of D. acutus were as previously described [29]. The raw reads were processed to obtain clean reads by removing adapter and low-quality sequences. Next, de novo transcriptome assembly was carried out using the Trinity program (v2.0.6). TIGR Gene Indices Clustering Tools (TGICL, v2.0.6) software was used to obtain the longest and most complete consensus transcripts by clustering the assembled datasets. Blast (v2.2.23) was used to annotate unigenes with Nt, Nr, COG, KEGG and SwissProt, Blast2GO (v2.5.0), Nr annotation results were used to GO annotate, and InterProScan5 (v5.11–51.0) was used to InterPro annotate. According to the results of functional annotation, the best-comparison fragments of unigenes were selected as the CDS of the unigene according to the database priority order of Nr, SwissProt, KEGG, and COG. Unigenes on the failed annotations were modeled by using the CDS predicted in the previous step, and predicted using ESTScan (v3.0.2). On the basis of the functional annotation, we searched proteins with a “Kunitz” keyword search in the annotated transcriptome library.

4.6. Pfam Platform Recognizing

Pfam is a sequence-based classifications database, that provides an alternative classification based on evolutionarily conserved repeat families [32]. Kunitz proteins were searched in the “sequence” box of Pfam database to recognize the specific Kunitz peptide sequences using hidden Markov models (HMMs). In the Pfam database, expectation (E-) values are calculated. An E-value is the number of hits that are expected to have a score equal to or better than this value by chance alone, and a good E-value is much less than 1 [53]. So, in this study, in order to obtain sequences that were highly consistent with the Kunitz domain feature, the E-value was limited to less than or equal to 10^−15.
4.7. Expression and Purification of Kunitz Peptides

The genes of all Kunitz peptides were synthesized and seamlessly cloned into the pPIC9k. Plasmids were linearized with the Sac I restriction enzyme (TaKaRa). Linearized plasmids were then transformed into competent P. pastoris GS115 cells using an electroporator (Bio-Rad, Hercules, CA, USA). Then, they were spread onto MD plates, and G418-resistant colonies were verified by PCR. Verified clones were cultured in BMGY (1% yeast extract, 1.34% YNB, 2% peptone, 1% glycerol, 100 mM sodium phosphate buffer pH 6, 4 × 10^{-5}% biotin) at 28.5 °C until suitable cell density was achieved. These cells were transferred to BMMY (1% yeast extract, 1.34% YNB, 2% peptone, 1% methanol, 100 mM sodium phosphate buffer pH 6, 4 × 10^{-5}% biotin), and cultured at 28.5 °C for 72 h, and 1% methanol was supplemented every 24 h to induce protein express. Yeast cultures containing Kunitz proteins were centrifuged to remove yeast cells. The supernatant was precipitated using 80% saturation concentration of ammonium sulfate and then centrifuged at 13,656 × g at 4 °C for 30 min. Precipitates were resuspended in 20 mM NaH₂PO₄–Na₂HPO₄ buffer (pH 7.0). Samples were dialyzed in a dialysis bag with a molecular cut-off 3.5 KDa (Millpore) in a 20 mM NaH₂PO₄–Na₂HPO₄ buffer (pH 7.0), and then loaded into a UniNTA-80Ni column (Nanomicro, Suzhou, China). The column was washed with 100 mL of NaH₂PO₄–Na₂HPO₄ buffer (pH 7.0), followed by 50 mL each of 20, 40, 200, and 600 mM imidazole diluted in a NaH₂PO₄–Na₂HPO₄ buffer (pH 7.0). Fractions eluted by 200 mM imidazole solution were collected and dialyzed against 20 mM NaH₂PO₄–Na₂HPO₄ buffer (pH 7.0), and then concentrated with 3 kDa ultrafiltration tubes (Millipore, Bedford, MA, USA). Sample concentration was estimated by BCA protein assay kit (Beyotime), and peptide yield was calculated by the concentration of the peptide multiplied by the volume, and then divided by the volume of the fermentation broth. Peptide purity was analyzed by Tricine–SDS-PAGE.

4.8. HPLC

DAKS1 purity was analyzed by HPLC on an Agilent ZORBAX 300 SB-C18 column (4.6 mm × 250 mm) under linear gradient elution conditions by using acetonitrile as the organic modifier, and trifluoroacetic acid (TFA) as the volatile buffer. Eluent A consisted of 0.1% TFA in distilled water (v/v), and eluent B consisted of 0.1% TFA in 100% acetonitrile (v/v). Gradient elution was carried out according to the following process: 0–20 min, B 5–50%; 20–22 min, B 50–90%; and 22–25 min, B 90%. Flow rate was 1 mL/min. UV absorbance was monitored at 214 nm.

4.9. LC–Q–TOF–MS Analysis

LC–Q–TOF–MS analysis was carried out using an Agilent Technologies (Santa Clara, CA, USA) 1290 Infinity Series liquid chromatograph coupled with an Agilent Technologies 6500 iFunnel Q–TOF LC/MS device equipped with an electrospray ionization Agilent Technologies Jet Stream ion source. Chromatographic separation was achieved on an Agilent ZORBAX 300 SB-C18 column (4.6 mm × 250 mm) (Agilent, Santa Clara, CA, USA). Injection volume was 20 µL. The mobile phase consisted of 0.1% formic acid in Milli-Q water (solvent A) and 0.1% formic acid in 100% acetonitrile (solvent B) at a flow rate of 0.5 mL/min. The mobile-phase gradient (10–60% B) was applied. Source nitrogen gas temperature was 325 °C, sheath gas flow was 12 L/min, and nebulizer pressure was 40 psig. Voltages were set at 4000 (capillary) and 175 V (fragmentor). Positive ions were acquired in the range of 100–3200 m/z for MS scans. Internal mass correction was enabled by using two reference masses at 121.0509 and 922.0098 m/z. Data acquisition and instrument control were performed using Agilent MassHunter Workstation software (B.06.01 SPI).

4.10. FXIa Inhibitory Activity Testing

The inhibitory activities of purified Kunitz peptides to FXIa were tested as previously [41]. In brief, FXIa (100 µL) was diluted with a buffer, TBS-BSA (10 mM Tris, 0.15 M NaCl, 0.3% BSA, pH 7.4) was preincubated with 50 µL different concentrations of proteins.
for 60 min at 37 °C, followed by the addition of 50 µL of the chromogenic substrate. The cleavage of substrate was continuously monitored at 405 nm for 60 min using a microplate reader (FEL-1). The slopes of the absorbance–time curves (V_i) were used to calculate the inhibitory activity of Kunitz peptides. BMMY medium was used as a control (slope of curve V_0). The inhibitory effect was calculated according to Equation (1):

\[
\text{Inhibitory rate (\%) = } \frac{(V_0 - V_i)}{V_0} \times 100
\]

where V_0 represents the slope of the control, and V_i represents the slope of the Kunitz peptides. IC_{50} was defined as the inhibitor concentration required to inhibit the activity of FXIa by 50%.

4.11. Protease Selectivity Testing

DAKS1 and serine protease (FXIa (0.5 nM), FXIIa (1 nM), kallikrein (0.5 nM), FXa (2.5 nM), and thrombin (1.42 nm)) were mixed with different molar ratios in TBS-BSA, and then incubated for 60 min at 37°C. The chromogenic substrate (CS-21 (66) (0.25 mM), TH 5253 (0.25 mM), CS-31 (02) (0.25 mM), CS-11 (22) (0.44 mM), CS-01 (38) (100 µM)) was added into the corresponding protease well, and absorbance at 405 nm was then continuously tested for 1 h using an FEL-1.

4.12. APTT and PT

Blood-clotting time was measured as previously described [41]. Briefly, 40 µL of PPP drawn from C57BL/6J male mice was added into test cuvettes and incubated with 10 µL DAKS1 or saline for 3 min at 37 °C. For the APTT assay, 50 µL of the APTT reagent was added and incubated for 3 min, and 50 µL prewarmed CaCl_2 was then added to start reactions. For the PT assay, 100 µL prewarmed PT reagent was added to start the reactions. Time to clot formation was recorded in triplicate.

4.13. Antithrombotic Activity Assay

The antithrombotic activity of DAKS1 was evaluated by a FeCl_3-induced carotid-artery injury model as previously described [54]. Briefly, C57BL/6J male mice were anesthetized with chloral hydrate (5%, 10 mL kg^{-1}) by i.p. injection and then fixed in a supine position on a heating pad (37 °C) to maintain body temperature. An incision was made directly into the skin of the common carotid-artery region. The fascia was then bluntly dissected, and a segment of the common carotid artery was exposed. Different concentrations of DAKS1 (0.26, 1.3, or 2.6 mg/kg), heparin sodium (2.7 mg/kg), or vehicle (saline) were injected through a tail vein. The mice were then transferred to moorFLPI-2 (model no: moorFLPI-2, Moor Instruments Limited, Millwey, Axminster, Devon, EX13 5HU, UK) and appropriately positioned under the laser. Ten minutes later, thrombus formation was induced by applying a piece of filter paper (1 mm × 2 mm) saturated with 6% FeCl_3 solution on the adventitial surface of the artery. Three minutes later, the filter paper was removed. The carotid artery was washed with saline three times. Blood flow was continuously monitored from the onset of injury until stable occlusion occurred or for 30 min if occlusion did not occur. Data were analyzed by moorFLPIReviewV50 software.

4.14. Transient Occlusion Model of Middle Cerebral Artery

The tMCAO model was used to induce focal cerebral ischemia as previously described [55]. Mice (C57BL/6J, male, 22–25 g) were anesthetized and fixed in a supine position on a heating pad to maintain at 37 °C during the whole period of surgery. An incision was made directly into the skin of the common carotid artery region, the proximal common carotid artery and external carotid artery (ECA) were ligated, and a polylsine-coated nylon monofilament (A4-162020, Beijing Xinong, China) was inserted from the common carotid artery to the left internal carotid artery to occlude the origin of the left middle cerebral artery. One hour later, DAKS1 (2.6 mg/kg) was injected by tail vein. Ten minutes later, the occluding filament was removed to allow for reperfusion. After 24 hours,
mice were sacrificed, and the brain was quickly removed, frozen for 20 min, and was cut into 2 mm thick coronal sections. Brain sections were then stained with 2% TTC (T8877-5G, Sigma, St. Louis, MO, USA). Stained slices were photographed and then analyzed by ImageJ software to quantify the infarcted area [56]. Bederson [48,57] and Zea Longa [49,58] scores were used to estimate neurological function.

4.15. Tail Bleeding-Time Assay

Bleeding time in mice was evaluated by a tail-cutting model as previously described [59]. Mice were randomly divided into four groups, namely, a vehicle (saline) group, a positive group (2.7 mg/kg of heparin sodium), and two sample groups (DAKS1 3.25 and 6.5 mg/kg). After steadily placing the anesthetized mice, the tail was washed with 75% ethanol. Samples and vehicle were injected by tail vein. Ten minutes later, the distal 2 mm segment of the tail was transected with a scalpel, and the tail was immediately immersed in 12 mL 0.9% saline warmed to 37 °C. The time was recorded until the cessation of the stream of blood. If the bleeding did not stop after 20 min, bleeding time was recorded as 20 min.

4.16. Statistical Analysis

Data were analyzed by using GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA). Results are expressed as mean ± SD values. The statistical significance of a two-sample comparison was evaluated by using an unpaired t-test, while multiple-sample comparisons were evaluated by using one-way ANOVA analysis, tested by Dunnett’s multiple comparisons. p < 0.05 was considered to be statistically significant.

5. Conclusions

In conclusion, by combining transcriptome sequencing and Pfam annotation, 10 Kunitz scaffold peptides were revealed from the venom of D. acutus. DAKS1, one of those peptides, showed potent inhibitory activity against FXIa, and inhibited thrombosis, preventing cerebral infarction in vivo without bleeding risk.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/ph14100966/s1. Figure S1: alignment of amino acid sequence of Kunitz domains from venom of D. acutus; Figure S2: DAKS1 inhibited trypsin; Figure S3: PN2KPI inhibited FeCl3-induced arterial thrombosis formation; Table S1: information of 11 proteins containing Kunitz domains from the annotated transcriptome library of the venom of D. acutus.

Author Contributions: Y.L., Z.J. and Y.K. designed the experiments. Y.L., S.J., Y.Z., Z.J., H.L., X.J. and Z.L. conducted the experiments. Y.Z. and Z.J. coordinated all the work and analyzed the results. Z.J., Y.K. and Y.Z. wrote the paper. All authors provided critical comments on the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by China Pharmaceutical University initiative program (no. CPU2018GY15).

Institutional Review Board Statement: All experiments were performed according to the guidelines and the regulations of the Ethical Committee of China Pharmaceutical University (CPU2019-S020, 19 December 2019).

Informed Consent Statement: Not applicable.

Data Availability Statement: Data is contained within the article and supplementary material.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Gebauer, M.; Skerra, A. Engineered Protein Scaffolds as Next-Generation Therapeutics. Annu. Rev. Pharmacol. Toxicol. 2020, 60, 391–415. [CrossRef] [PubMed]
2. Simeon, R.; Chen, Z. In Vitro-Engineered Non-Antibody Protein Therapeutics. Protein Cell 2018, 9, 3–14. [CrossRef]
3. Löblom, J.; Frejd, F.Y.; Stahl, S. Non-immunoglobulin Based Protein Scaffolds. Curr. Opin. Biotechnol. 2011, 22, 843–848. [CrossRef] [PubMed]
4. Smith, H.S.; Deer, T.R. Safety and Efficacy of Intrathecal Ziconotide in the Management of Severe Chronic Pain. *Ther. Clin. Risk Manag.* **2009**, *5*, 521–534. [CrossRef]
5. Layer, P.; Stanghellini, V. Review Article: Linacotide for the Management of Irritable Bowel Syndrome with Constipation. *Aliment. Pharmacol. Ther.* **2014**, *39*, 371–384. [CrossRef] [PubMed]
6. Vazquez-Lombardi, R.; Phan, T.G.; Zimmermann, C.; Lowe, D.; Jermutus, L.; Christ, D. Challenges and Opportunities for Non-Antibody Scaffold Drugs. *Drug Discov. Today* **2015**, *20*, 1271–1283. [CrossRef] [PubMed]
7. Mishra, M. Evolutionary Aspects of the Structural Convergence and Functional Diversification of Kunitz-Domain Inhibitors. *J. Mol. Evol.* **2020**, *88*, 537–548. [CrossRef] [PubMed]
8. Leung, D.; Abbenante, G.; Fairlie, D.P. Protease Inhibitors: Current Status and Future Prospects. *J. Med. Chem.* **2000**, *43*, 305–341. [CrossRef] [PubMed]
9. Laskowski, M.; Kato, I. Protein Inhibitors of Proteinases. *Annu. Rev. Biochem.* **1980**, *49*, 593–626. [CrossRef] [PubMed]
10. Hosse, R.J.; Rothe, A.; Power, B.E. A New Generation of Protein Display Scaffolds for Molecular Recognition. *Protein Sci.* **2006**, *15*, 14–27. [CrossRef]
11. Levy, R.J.; Lumry, W.R.; McNeil, D.L.; Li, H.H.; Campion, M.; Horn, P.T.; Pullman, W.E. EDEMA4: A Phase 3, Double-Blind Study of Subcutaneous Ecallantide Treatment for Acute Attacks of Hereditary Angioedema. *Ann. Allergy Asthma Immunol.* **2010**, *104*, 523–529. [CrossRef]
12. Schneider, L.; Lumry, W.; Vegh, A.; Williams, A.H.; Schmalbach, T. Critical Role of Kallikrein in Hereditary Angioedema Pathogenesis: A Clinical Trial of Ecallantide, a Novel Kallikrein Inhibitor. *J. Allergy Clin. Immunol.* **2007**, *120*, 416–422. [CrossRef]
13. Martello, J.L.; Woytowish, M.R.; Chambers, H. Ecallantide for Treatment of Acute Attacks of Hereditary Angioedema. *Am. J. Health Syst. Pharm.* **2012**, *69*, 651–657. [CrossRef]
14. Roberts, B.L.; Markland, W.; Ley, A.C.; Kent, R.B.; White, D.W.; Guterman, S.K.; Ladner, R.C. Directed Evolution of a Protein: Selection of Potent Neutrophil Elastase Inhibitors Displayed on M13 Fusion Phage. *Proc. Natl. Acad. Sci. USA* **1992**, *89*, 2429–2433. [CrossRef] [PubMed]
15. Attucci, S.; Gauthier, A.; Korkmaz, B.; DelÂ Pine, P.; Martino, M.L.F.; Saudubray, F.O.; Diet, P.; Gauthier, F. EPI-hNE4, a Proteolysis-Resistant Inhibitor of Human Neutrophil Elastase and Potential Anti-Inflammatory Drug for Treating Cystic Fibrosis. *J. Pharmacol. Exp. Ther.* **2006**, *318*, 803–809. [CrossRef] [PubMed]
16. Dunlevy, F.K.; Martin, S.L.; de Courcey, F.; Elborn, J.S.; Ennis, M. Anti-Inflammatory Effects of DX-890, a Human Neutrophil Elastase Inhibitor. *J. Cyst. Fibros.* **2012**, *11*, 300–304. [CrossRef] [PubMed]
17. Müller, F.; Gailani, D.; Renné, T. Factor XI and XII As Antithrombotic Targets. *Curr. Opin. Hematol.* **2011**, *18*, 349–355. [CrossRef]
18. Salomon, O.; Steinberg, D.M.; Zucker, M.; Varon, D.; Zivelin, A.; Seligsohn, U. Patients with Severe Factor XI Deficiency Have a Reduced Incidence of Deep-Vein Thrombosis. *Thromb. Haemost.* **2011**, *105*, 269. [CrossRef]
19. Salomon, O.; Steinberg, D.M.; Koren-Morag, N.; Tanne, D.; Seligsohn, U. Reduced Incidence of Ischemic Stroke in Patients with Severe Factor XI Deficiency. *Blood* **2008**, *111*, 4113–4117. [CrossRef] [PubMed]
20. Rosen, E.D.; Gailani, D.; Castellino, F.J. FXI is Essential for Thrombus Formation Following FeCl3-Induced Injury of the Carotid Artery in the Mouse. *Thromb. Haemost.* **2002**, *87*, 774–776.
21. Wang, X.; Cheng, Q.; Xu, L.; Feuerstein, G.Z.; Hsu, M.Y.; Smith, P.L.; Seiffert, D.A.; Schumacher, W.A.; Ogletree, M.L.; Gailani, D. Effects of Factor IX or Factor XI Deficiency on Ferric Chloride-Induced Carotid Artery Occlusion in Mice. *J. Thromb. Haemost.* **2005**, *3*, 695–702. [CrossRef]
22. Wang, X.; Smith, P.L.; Hsu, M.Y.; Gailani, D.; Schumacher, W.A.; Ogletree, M.L.; Seiffert, D.A. Effects of Factor XI Deficiency on Ferric Chloride-Induced Vena Cava Thrombosis in Mice. *J. Thromb. Haemost.* **2006**, *4*, 1982–1988. [CrossRef] [PubMed]
23. Wu, W.; Li, H.; Navaneetham, D.; Reichenbach, Z.W.; Tuma, R.F.; Walsh, P.N. The Kunitz Protease Inhibitor Domain of Protease Nexitin-2 Inhibits Factor Xla and Murine Carotid Artery and Middle Cerebral Artery Thrombosis. *Blood* **2012**, *120*, 671–677. [CrossRef] [PubMed]
24. Oltersdorff, T.; Fritz, L.C.; Schenk, D.B.; Lieberburg, I.; Johnson-Wood, K.L.; Beattie, E.C.; Ward, P.J.; Blacher, R.W.; Dovey, H.F.; Sinha, S. The Secreted Form of the Alzheimer’s Amyloid Precursor Protein with the Kunitz Domain Is Protease Nexitin-II. *Nature* **1989**, *341*, 144–147. [CrossRef] [PubMed]
25. Chen, W.; Carvalho, L.P.D.; Chan, M.Y.; Kini, R.M.; Kang, T.S. Fassxiator, a Novel Factor Xla Inhibitor from Snake Venom, and Its Site-Specific Mutagenesis to Improve Potency and Selectivity. *J. Thromb. Haemost.* **2015**, *13*, 248–261. [CrossRef]
26. Decrem, Y.; Rath, G.; Blasioli, V.; Cauchie, P.; Robert, S.; Beaufays, J.; Frene, J.M.; Feron, O.; Dogne, J.M.; Dessy, C.; et al. Ir- CPI, a Coagulation Contact Phase Inhibitor from the Tick Ixodes ricinus, Inhibits Thrombus Formation without Impairing Hemostasis. *J. Exp. Med.* **2009**, *206*, 2381–2395. [CrossRef]
27. Pireaux, V.; Tassignon, J.; Demoulin, S.; Derochette, S.; Borenstein, N.; Ente, A.; Fiette, L.; Douxfils, J.; Lancellotti, P.; Guyaux, M.; et al. Anticoagulation with an Inhibitor of Factors Xla and Xlla During Cardiopulmonary Bypass. *J. Am. Coll. Cardiol.* **2019**, *74*, 2178–2189. [CrossRef]
28. De Oliveira, C.F.R.; Oliveira, C.T.; Taveira, G.B.; de Oliveira Mello, E.; Gomes, V.M.; Macedo, M.L.R. Characterization of a Kunitz Trypsin Inhibitor from *Enterolobium timbouva* with Activity against Candida Species. *Int. J. Biol. Macromol.* **2018**, *119*, 645–653. [CrossRef]
29. Liao, Q.; Li, S.; Siu, S.W.I.; Yang, B.; Huang, C.; Chan, J.Y.; Morlighem, J.R.L.; Wong, C.T.T.; Rádis-Baptista, G.; Lee, S.M. Novel Kunitz-like Peptides Discovered in the Zoanthid Palypea caribaeorum through Transcriptome Sequencing. *J. Proteome Res.* 2018, 17, 891–902. [CrossRef]

30. Emsley, J.; McEwan, P.A.; Gailani, D. Structure and Function of Factor XI. *Blood* 2010, 115, 2569–2577. [CrossRef]

31. Ma, D.; Mizurini, D.M.; Assumpção, T.C.F.; Li, Y.; Qi, Y.; Kotsyfakis, M.; Ribeiro, J.M.C.; Monteiro, R.Q.; Francischetti, I.M.B. Desmolaris, a Novel Factor Xla Anticoagulant from the Salivary Gland of the Vampire Bat (*Desmodus rotundus*) Inhibits Inflammation and Thrombosis In Vivo. *Blood* 2013, 122, 4094–4106. [CrossRef]

32. Chen, T.F.; Li, K.K.; Zhu, E.F.; Opel, C.F.; Kauke, M.J.; Kim, H.; Atolia, E.; Wittrup, K.D. Artificial Anti-Tumor Opsonizing Proteins with Fibronectin Scaffolds Engineered for Specificity to Each of the Murine FcgammaR Types. *J. Biol. Mol.* 2018, 430, 1786–1798. [CrossRef]

33. Bloom, L.; Calabro, V. FN3: A New Protein Scaffold Reaches the Clinic. *Drug Discov. Today* 2009, 14, 949–955. [CrossRef]

34. Wurch, T.; Pierre, A.; Depil, S. Novel Protein Scaffolds as Emerging Therapeutic Proteins: From Discovery to Clinical Proof-of-Concept. *Trends Biotechnol.* 2012, 30, 575–582. [CrossRef] [PubMed]

35. Owens, B. Faster, Deeper, Smaller–The Rise of Antibody-Like Scaffolds. *Nat. Biotechnol.* 2017, 35, 602–603. [CrossRef]

36. Nuttall, S.D.; Walsh, R.B. Display Scaffolds: Protein Engineering for Novel Therapeutics. *Curr. Opin. Pharmacol.* 2008, 8, 609–615. [CrossRef] [PubMed]

37. Koide, A.; Bailey, C.W.; Huang, X.; Koide, S. The Fibronectin Type III Domain as a Scaffold for Novel Binding Proteins. *Cell* 2005, 122, 891–902. [CrossRef] [PubMed]

38. Župunski, V.; Kordiš, D.; Gubenšek, F. Adaptive Evolution in the Snake Venom Kunitz/BPTI Protein Family. *Toxins* 2018, 10, 332. [CrossRef] [PubMed]

39. Schlehuber, S.; Skerra, A. The Menagerie of Human Lipocalins: A Natural Protein Scaffold for Molecular Recognition of Physiological Compounds. *Acc. Chem. Res.* 2015, 48, 976–985. [CrossRef] [PubMed]

40. Morgenstern, D.; King, G.F. The Venom Optimization Hypothesis Revisited. *Toxicon* 2013, 63, 120–128. [CrossRef]

41. Chen, M.; Ye, X.; Ming, X.; Chen, Y.; Wang, Y.; Su, X.; Su, W.; Kong, Y. A Novel Direct Factor Xa Inhibitory Peptide with Anti-Platelet Aggregation Activity from *Deinagkistrodon acutus* Venom. *Sci. Rep.* 2015, 5, 10846. [CrossRef]

42. Kong, Y.; Sun, Q.; Zhao, Q.; Zhang, Y. Purification and Characterization of a Novel Antiplatelet Peptide from *Deinagkistrodon acutus* Venom. *Toxins* 2018, 10, 332. [CrossRef] [PubMed]

43. Župunski, V.; Kordiš, D.; Gubenšek, F. Adaptive Evolution in the Snake Venom Kunitz/BPTI Protein Family. *Toxins* 2018, 10, 332. [CrossRef] [PubMed]

44. Rowan, E.G.; Harvey, A.L. Snake Toxins from Mamba Venoms: Unique Tools for the Physiologist. *Exp. Transl. Stroke Med.* 2015, 6, 15. [CrossRef]

45. Lehmann, A. Ecallantide (DX-88), a Plasma Kallikrein Inhibitor for the Treatment of Hereditary Angioedema and the Prevention of Blood Loss in On-Pump Cardiothoracic Surgery. *Expert Opin. Biol. Ther.* 2008, 8, 1187–1199. [CrossRef]

46. Kanchongkittiphon, W.; Kabil, N.; Bacharier, L.B.; Kitcharoensakkul, M. Ecallantide: An Alternative Treatment of Refractory Angioedema in Adolescents with Systemic Lupus Erythematosus. *J. Allergy Clin. Immunol. Pract.* 2020, 8, 1115–1116. [CrossRef]

47. Navaneetham, D.; Jin, L.; Pandey, P.; Strickler, J.E.; Babine, R.E.; Abdel-Meguid, S.S.; Walsh, P.N. Structural and Mutational Analyses of the Molecular Interactions between the Catalytic Domain of Factor Xla and the Kunitz Protease Inhibitor Domain of Protease Nexin 2. *J. Biol. Chem.* 2005, 280, 36165–36175. [CrossRef]

48. Župunski, V.; Kordiš, D.; Gubenšek, F. Adaptive Evolution in the Snake Venom Kunitz/BPTI Protein Family. *FEBS Lett.* 2003, 547, 131–136. [CrossRef]

49. Rowan, E.G.; Harvey, A.L. Snake Toxins from Mamba Venoms: Unique Tools for the Physiologist. *Acta Chim. Slov.* 2011, 58, 689–692. [CrossRef]

50. Lehmann, A. Ecallantide (DX-88), a Plasma Kallikrein Inhibitor for the Treatment of Hereditary Angioedema and the Prevention of Blood Loss in On-Pump Cardiothoracic Surgery. *Expert Opin. Biol. Ther.* 2008, 8, 1187–1199. [CrossRef]

51. Schiefler, A.; Skerra, A. The Menagerie of Human Lipocalins: A Natural Protein Scaffold for Molecular Recognition of Physiological Compounds. *Acc. Chem. Res.* 2015, 48, 976–985. [CrossRef] [PubMed]

52. Župunski, V.; Kordiš, D.; Gubenšek, F. Adaptive Evolution in the Snake Venom Kunitz/BPTI Protein Family. *Toxins* 2018, 10, 332. [CrossRef] [PubMed]

53. Župunski, V.; Kordiš, D.; Gubenšek, F. Adaptive Evolution in the Snake Venom Kunitz/BPTI Protein Family. *Toxins* 2018, 10, 332. [CrossRef] [PubMed]

54. Župunski, V.; Kordiš, D.; Gubenšek, F. Adaptive Evolution in the Snake Venom Kunitz/BPTI Protein Family. *Toxins* 2018, 10, 332. [CrossRef] [PubMed]

55. Župunski, V.; Kordiš, D.; Gubenšek, F. Adaptive Evolution in the Snake Venom Kunitz/BPTI Protein Family. *Toxins* 2018, 10, 332. [CrossRef] [PubMed]

56. Župunski, V.; Kordiš, D.; Gubenšek, F. Adaptive Evolution in the Snake Venom Kunitz/BPTI Protein Family. *Toxins* 2018, 10, 332. [CrossRef] [PubMed]

57. Župunski, V.; Kordiš, D.; Gubenšek, F. Adaptive Evolution in the Snake Venom Kunitz/BPTI Protein Family. *Toxins* 2018, 10, 332. [CrossRef] [PubMed]
56. Krupka, J.; May, F.; Weimer, T.; Pragst, I.; Kleinschnitz, C.; Stoll, G.; Panousis, C.; Dickneite, G.; Nolte, M.W. The Coagulation Factor XIIa Inhibitor rHA-Infestin-4 Improves Outcome after Cerebral Ischemia/Reperfusion Injury in Rats. *PLoS ONE* **2016**, *11*, e0146783. [CrossRef] [PubMed]

57. Bederson, J.B.; Pitts, L.H.; Tsuji, M.; Nishimura, M.C.; Davis, R.L.; Bartkowski, H. Rat Middle Cerebral Artery Occlusion: Evaluation of the Model and Development of a Neurologic Examination. *Stroke* **1986**, *17*, 472–476. [CrossRef] [PubMed]

58. Zheng, X.W.; Yang, W.T.; Chen, S.; Xu, Q.Q.; Shan, C.S.; Zheng, G.Q.; Ruan, J.C. Neuroprotection of Catalpol for Experimental Acute Focal Ischemic Stroke: Preclinical Evidence and Possible Mechanisms of Antioxidation, Anti-Inflammation, and Antiapoptosis. *Oxid. Med. Cell Longev.* **2017**, *2017*, 5058609. [CrossRef] [PubMed]

59. Ren, S.; Liu, Z.; Cao, Y.; Hua, Y.; Chen, C.; Guo, W.; Kong, Y. A Novel Protease-Activated Receptor 1 Inhibitor from the Leech *Whitmania pigra*. *Chin. J. Nat. Med.* **2019**, *17*, 591–599. [CrossRef]